while people with haemophilia B do not have enough Factor IX. In the 1970s, a new treatment using donated human blood plasma was developed to replace these clotting agents. But whole batches were ...
Be Biopharma, Inc. ("Be Bio"), a clinical-stage company pioneering engineered B Cell Medicines (BCMs), today announced two key updates at the 66th ASH Annual Meeting in San Diego, CA. These updates ...
Elliott Mason was born unable to make enough of clotting factor IX, a crucial protein which helps to stop us bleeding A "transformational" therapy has effectively cured people with the bleeding ...
Novo Nordisk has filed its long-acting factor IX, nonacog beta pegol in the US for haemophilia B. Nonacog beta pegol is a glycopegylated recombinant factor IX with a longer half-life, developed ...